F.D.A. Panel Rejects Drug for Obesity
The drug, known as rimonabant and already sold in 37 countries under the brand name Acomplia, was approved by the European Medical Agency in June 2006. Sanofi had intended to market it in the United States as Zimulti.
The drug is indicated for treating obesity, but has not been shown to...
To view the full article, register now.